Literature DB >> 28976502

Rational antibiotic sustainability for transrectal prostate biopsy prophylaxis.

Deepak K Pruthi1, Michael A Liss1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28976502     DOI： 10.1038/nrurol.2017.158

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis.

Authors:  Michael A Liss; William Kim; Dena Moskowitz; Richard J Szabo
Journal:  J Urol       Date:  2015-04-03       Impact factor: 7.450

2.  Sepsis: Prophylactic antibiotic for prostate biopsy: the carbapenem gamble.

Authors:  Deepak K Pruthi; Michael A Liss
Journal:  Nat Rev Urol       Date:  2017-05-23       Impact factor: 14.432

3.  Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England.

Authors:  Eleni Anastasiadis; Jan van der Meulen; Mark Emberton
Journal:  Int J Urol       Date:  2014-09-26       Impact factor: 3.369

4.  Prophylactic ciprofloxacin for prostate biopsy: a losing bet?

Authors:  Maxim Bloomfield; Timothy Blackmore
Journal:  Nat Rev Urol       Date:  2017-10-04       Impact factor: 14.432

5.  Routine Ertapenem Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy does Not Select for Carbapenem Resistant Organisms: A Prospective Cohort Study.

Authors:  Maxim G Bloomfield; Matthew J Page; Alice G McLachlan; Rodney C Studd; Timothy K Blackmore
Journal:  J Urol       Date:  2017-03-10       Impact factor: 7.450

6.  Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy.

Authors:  Michael A Liss; Stephen A Taylor; Deepak Batura; Deborah Steensels; Methee Chayakulkeeree; Charlotte Soenens; G Gopal Rao; Atreya Dash; Samuel Park; Nishant Patel; Jason Woo; Michelle McDonald; Unwanaobong Nseyo; Pooya Banapour; Stephen Unterberg; Thomas E Ahlering; Hendrik Van Poppel; Kyoko Sakamoto; Joshua Fierer; Peter C Black
Journal:  J Urol       Date:  2014-06-10       Impact factor: 7.450

7.  Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study.

Authors:  Evangelos I Kritsotakis; Constantinos Tsioutis; Maria Roumbelaki; Athanasia Christidou; Achilleas Gikas
Journal:  J Antimicrob Chemother       Date:  2011-03-31       Impact factor: 5.790

8.  Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach; Marie Synnestvedt; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254

9.  Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study.

Authors:  Matthew E Falagas; Petros I Rafailidis; Diamantis Kofteridis; Simona Virtzili; Fotini C Chelvatzoglou; Vassiliki Papaioannou; Sofia Maraki; George Samonis; Argyris Michalopoulos
Journal:  J Antimicrob Chemother       Date:  2007-09-20       Impact factor: 5.790

10.  Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy.

Authors:  Stephen Taylor; Joseph Margolick; Zeid Abughosh; S Larry Goldenberg; Dirk Lange; William R Bowie; Robert Bell; Diane Roscoe; Lindsay Machan; Peter Black
Journal:  BJU Int       Date:  2013-03-06       Impact factor: 5.588
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.